RxDoctor Payments Data

Mark Rodriguez, MD

Family Medicine · San Antonio, TXNPI 1982708111

Payments from drug & device makers

$18,864in general payments, 2019–2025

Across 1,044 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Bayer$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • plus $8K from 52 others

What the payments were for

  • Food & beverage$18,63899%
  • Education$2271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)180$2,784
Novo Nordisk130$2,489
Lilly USA, LLC122$2,041
Bayer73$1,361
AstraZeneca47$1,333
Pfizer126$1,283
Takeda Pharmaceuticals U.S.A., Inc.46$858
Amarin Pharma, Inc.33$553
Axsome Therapeutics, Inc.15$509
GSK18$455
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)20$447
Boehringer Ingelheim17$418
Antares Pharma, Inc.17$284
Merck21$280
Xeris Pharmaceuticals, Inc.20$259
Johnson & Johnson(2 entities)13$237
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$231
Corcept Therapeutics6$228
Ardelyx, Inc.5$224
Esperion Therapeutics, Inc.14$222
Amgen(2 entities)13$218
Teva Pharmaceuticals USA, Inc.3$152
Astellas Pharma US Inc4$144
Abbott7$130
Phathom Pharmaceuticals, Inc.7$128
Sanofi-aventis U.S. LLC7$127
Jazz Pharmaceuticals Inc.1$125
Ironwood Pharmaceuticals, Inc1$100
Althera Pharmaceuticals LLC6$100
Otsuka America Pharmaceutical, Inc.4$94
Bausch Health US, LLC5$83
Biohaven Pharmaceuticals, Inc.4$75
Nevro Corp.3$73
Kowa Pharmaceuticals America, Inc.4$69
Tolmar, Inc.4$68
Idorsia Pharmaceuticals US Inc4$67
Agios Pharmaceuticals, Inc.2$43
Dexcom, Inc.2$43
Nabriva Therapeutics, PLC3$43
Biohaven Pharmaceutical Holding Company Ltd.2$42
Exact Sciences2$40
Inspire Medical Systems, Inc.1$39
Halozyme Inc2$35
Vertex1$32
Zyla Life Sciences, Inc.2$29
Novartis2$29
Vanda Pharmaceuticals Inc.2$28
Alk-abello, Inc1$28
Si-bone, Inc.1$24
Intuitive Surgical1$23
Ultragenyx Pharmaceutical Inc.1$21
Insmed, Inc.1$21
Acerus Pharmaceuticals Corporation1$19
Eisai Inc.1$18
Paratek Pharmaceuticals, Inc.1$18
Boston Scientific1$16
Arbor Pharmaceuticals, Inc.1$13
Vistapharm, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,864 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$286,635
Medicare patients
524
Services billed
2,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$131,805
MounjaroTirzepatide67$70,381
JardianceEmpagliflozin52$61,324
TrulicityDulaglutide28$38,456
RybelsusSemaglutide20$23,574
UbrelvyUbrogepant15$21,101
OxycontinOxycodone Hcl12$18,095
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$17,340
EliquisApixaban16$17,252
FarxigaDapagliflozin Propanediol14$17,162
JanuviaSitagliptin Phosphate18$17,149
MyrbetriqMirabegron11$11,213
KerendiaFinerenone16$11,107
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,248
VascepaIcosapent Ethyl15$6,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,489$155,379124 claims
Lilly USA, LLCMounjaro, Trulicity$2,041$108,83795 claims
Boehringer IngelheimJardiance$418$61,32452 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,333$25,41027 claims
AbbVieUbrelvy, Synthroid$2,784$23,93150 claims
GSKTrelegy Ellipta$455$17,34014 claims
PfizerEliquis$1,283$17,25216 claims
MerckJanuvia$280$17,14918 claims
Astellas Pharma US IncMyrbetriq$144$11,21311 claims
BayerKerendia$1,361$11,10716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →